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Abstract: Met is a tyrosine kinase receptor that is considered to be a proto-oncogene.  
The hepatocyte growth factor (HGF)-Met signaling system plays an important role in tumor 
growth, invasion, and metastasis in many types of malignancies. Furthermore, Met expression 
has been reported to be a useful predictive biomarker for disease progression and patient 
survival in these malignancies. Many studies have focused on the clinical significance and 
prognostic role of Met in urological cancers, including prostate cancer (PCa), renal cell 
carcinoma (RCC), and urothelial cancer. Several preclinical studies and clinical trials are in 
progress. In this review, the current understanding of the pathological role of Met in cancer 
cell lines, its clinical significance in cancer tissues, and its predictive value in patients with 
urological cancers are summarized. In particular, Met-related malignant behavior in 
castration-resistant PCa and the different pathological roles Met plays in papillary RCC and 
other histological types of RCC are the subjects of focus. In addition, the pathological 
significance of phosphorylated Met in these cancers is shown. In recent years, Met has been 
recognized as a potential therapeutic target in various types of cancer; therapeutic strategies 
used by Met-targeted agents in urological cancers are summarized in this review. 
Keywords: Met; prostate cancer; renal cell carcinoma; urothelial cancer; pathological 
features; survival; target therapy 
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1. Introduction 
Met is a member of cell surface tyrosine kinase (TK) family that was isolated from a chemically 
transformed human malignant cell line in the 1980s [1]. Hepatocyte growth factor (HGF, also known as 
scatter factor) is the only endogenous ligand of MET, and HGF/Met signaling can regulate various 
cellular processes, such as proliferation, apoptosis, and migration [2,3]. Therefore, this signaling is 
important in physiological activities including maintenance of homeostasis and wound repair [3–5].  
Since cell proliferation, migration, and angiogenesis are important steps in malignant cell dissemination, 
many investigators have paid special attention to the relationship between Met overexpression and 
malignant aggressiveness, including tumor invasion and metastasis. A recent review indicated that 
enhanced HGF/Met signaling is found in various types of cancers [6]. In addition, Met expression  
has been reported to be positively associated with tumor growth, invasion, and metastasis in cancer 
patients [7]. Indeed, our previous reports showed that Met played a crucial role in tumor growth, 
metastasis, and prognosis in patients with bladder cancer and renal cell carcinoma [8,9].  
Many investigators have suggested that evaluation of the expression and biological activity of Met  
is important in understanding the pathological characteristics, malignant behavior, and strategies of 
observation and treatment for patients with malignancies. However, it should be noted that there is  
a wide range of variability in the quantification and pathological significance of Met in previous reports. 
In particular, variability has been demonstrated in the immunohistochemical technique most commonly 
used for evaluation of Met expression in animal and human tissues. Possible reasons that have been 
suggested for such discrepancies include differences in sample size, antibodies used, methods of 
evaluation, and condition of the tissue samples [8]. It has subsequently been suggested that quantification 
of phosphorylated Met could be a useful marker of Met signaling activity and Met-related pathological 
functions; this is discussed in greater detail below. Aberrant MET signaling is the cause of the pathological 
behavior and malignant aggressiveness of Met in human malignancies. As shown in Figure 1, it is 
regulated through various mechanisms.  
The common mechanism of MET signaling activation is transcriptional deregulation, resulting in 
MET overexpression in malignant cells. In addition, MET gene mutation and amplification of the MET 
gene locus, resulting in receptor overexpression, are also characterized aberrancies. Mutation of the MET 
gene is thought to be a rare event in cancer, but it is often found in papillary renal cell carcinoma (RCC) 
and childhood hepatocellular carcinoma [9,10]. Conversely, MET gene copy number gain has been 
reported to be common and is associated with a poor prognosis in patients with lung cancer [11]. The 
fact that the activation and up-regulation mechanisms of Met in malignancies depend on the type of 
cancer and background of the patient should be noted when discussing the clinical significance of Met. 
HGF-Met signaling has been reported to interact with various cancer-related molecules that promote 
tumor growth and metastasis. For example, HGF-Met signaling can promote angiogenesis though 
interaction with the vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) signaling 
system [3,12]. In addition to VEGF, HGF-Met signaling has been known to mediate angiogenesis 
through regulation of thrombospondin (TSP)-1, which is a known anti-angiogenic factor [13]. 
Interestingly, HGF-Met signaling has been found to mediate angiogenesis through positive regulation 
of VEGF and negative regulation of TSP-1 [13]. Furthermore, Met is reported to be associated with 
cancer-related activities through various mechanisms including carcinogenesis, cell migration, and 
chemoresistance [14–16]. 
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Figure 1. In cancer, HGF-Met signaling is up-regulated by various systems, including  
over-expression or mutation of Met and increased HGF production. 
 
There are three different strategies to inhibit Met signaling: antagonism of receptor-ligand interaction; 
inhibition of the TK catalytic activity; and inhibition of the interaction between the receptor and 
intracellular signaling effectors. By understanding the detailed structure, function, and regulative 
mechanisms of HGF-Met signaling, it has been possible to develop various Met inhibitors (Table 1).  
At present, Met inhibitors are divided into two major classes: monoclonal antibodies that compete with 
HGF for binding to Met and Met TK inhibitors (TKIs). In Table 1, Met inhibitors for various types of 
malignancies are shown, including those for urological cancers; some of these drugs are in preclinical 
development and others are in or have completed clinical trials. However, as shown in Table 1, the 
number of Met-targeted therapies in urological cancer clinical trials is limited. Therefore, the 
pathological role, clinical significance, and predictive value of Met, and the clinical development of 
Met-targeted therapy in urological cancers, including PCa, RCC, and urothelial cancer, are reviewed in 
this manuscript. 
Table 1. Met-targeting therapies for malignancies including urological cancers. 
 Type of Malignancy Urological Cancers (Phase) 
Anti-Met mAbs   
LY-2875358 Lymphoma  
Onartuzumab Breast, Colon, Lung, Stomach  
Small anti-MET TKIs   
Cabozantinib (XL 184) Brain, Breast, Lung, Pancreas, Thyroid * Prostate (II/III), Renal (II/III) 
Crizotinib  Lung *, Lymphoma   
Foretinib (XL 880) Breast, Head and neck, Lung, Stomach  Papillary renal (II) 
Golvatinib (E7050) Brain, Head and neck, Liver, Stomach  
MGCD 265 Lung  
Tivantinib (ARQ 197) Breast, Colon, Liver, Lung, Myeloma Prostate (II), Renal (I/II) 
* Approved by U.S. Food and Drug Administration (PDA). 
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2. Prostate Cancer 
PCa is the most common cancer in men. In the United States, it is estimated that 29,000 patients  
died from PCa in 2013 [17]. Numerous studies have investigated the pathological characteristics and 
cancer-related changes to the molecules and genes of PCa cells in vivo and in vitro. As mentioned above, 
the Met TK receptor has been shown to play a role in the proliferation and progression of many types of 
malignancy, including PCa. In this section, the pathological significance, prognostic roles, and possible 
therapeutic use of targeting Met in PCa are discussed. In addition, the pathological role of Met expression 
in castration-resistant PCa (CRPC) is shown. 
2.1. The Function of Met Expression in Prostate Cancer Cell Lines 
Numerous studies have demonstrated that in human PCa cell lines the MET signaling system plays 
an important role in cell survival by enhancing cell proliferation and suppressing apoptosis [18,19].  
In addition, knockout of the Met gene inhibits tumor cell metastasis [20]. Recent studies have shown 
that the expression of the tumor suppressor miR-34 is inversely correlated with MET expression in  
PC-3 cells [21]. In addition, it has been suggested that miR-34 may inhibit the migration of PCa cells by 
regulating Met activity. Thus, several reported suggested that Met plays a critical role in the malignant 
aggressiveness of PCa cells.  
In discussing the pathological mechanisms of Met in PCa, it is important to consider in vivo and  
in vitro androgen-sensitivity. PCa cells initially depend upon androgen stimulation, through androgen 
receptor signaling, for cell survival and malignant behavior. In fact, androgen deprivation is the standard 
treatment for patients with advanced PCa. However, as the cells become androgen-independent, they 
become more aggressive. Most recurrent and metastatic tumors that occur after androgen-deprivation 
therapy include castration-resistant PCa cells [22]. There is currently no curative therapy for CRPC,  
and patients tend to die due to invasion and metastasis-related pathological conditions. 
Among the most widely used human PCa cell lines, MET protein is highly expressed in androgen 
receptor-negative cell lines (PC-3 and DU145) but only minimally expressed in androgen receptor-positive 
cell lines (LNCaP, LAPC-4, CWR22, and LUCaP) [23]. In these cell lines, the MET mRNA expression 
levels are reported to be similar to the protein levels. The androgen receptor-negative PCa cells, PC3 
and DU145, have a higher malignant potential, including increased cell proliferation and migration, 
suppressed apoptosis, and a higher rate of angiogenesis when compared to androgen-receptor-positive 
cells. Based on these findings, it has been hypothesized that the loss of androgen receptor expression 
and increased Met expression contribute to the malignant potential of CRPC. Interestingly, continuous 
androgen-deprivation of the androgen-sensitive PCa cell line, LNCaP, results in decreased androgen 
receptor expression and increased Met expression [24]. In addition to these in vitro studies, the 
pathological activity of Met in CRPC has also been confirmed using CRPC cell lines and animal 
xenograft models [23,25]. From these findings, Met is speculated to be potential therapeutic target for 
CRPC. In fact, Met inhibitors have been shown to suppress cell proliferation and tumor growth of 
androgen receptor-negative (androgen-insensitive) PCa cell lines [26].  
Furthermore, the importance of cancer stem cells (CSCs) in prostate cancer should be emphasized. 
According to the CSC hypothesis, tumor growth is sustained by a subpopulation of cancer 
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stem/progenitor-like cells. Like other malignancies, human prostate cancer tissue contains neoplastic 
cells with self-renewal and clonogenic potential, which can be enriched and perpetuated in  
prostaspheres [27]. When MET is activated in prostate cancer cells, a stem-like phenotype is induced. 
MET is thought to regulate tumor infiltration in surrounding tissues by acquisition of a stem-like 
phenotype [28]. 
2.2. Expression/Activation of MET in Prostate Cancer and Correlation with Clinicopathological 
Characteristics 
Some investigators have showed the relationships between Met expression and clinicopathological 
features in patients with prostate cancer [29–34]. We list a summary of their results as Table 2. In regard 
to Gleason score, several reports have indicated MET expression had a positive correlation [29,31,33,34]. 
On the other hand, there is little information regarding its correlation with TNM stage. Indeed, there is 
one study that indicates that the expression of MET is not significantly associated with tumor stage, 
nodal stage, or surgical margin status [32]. Furthermore, although MET expression in metastatic tumors 
is higher than in primary PCa, it is not a significant predictive factor in patients with a Gleason score of 
6 or 7 [31]. Thus, further detailed studies are necessary to decisively determine the clinical significance 
and pathological role of MET in PCa patients.  
Table 2. Relationship between Met expression and pathological features in prostate cancer. 
Year No. pts 
Clinicopathological Features 
Ref. 
High GS High T Stage Presence of LN Metastasis Presence of Distant Metastasis 
1995 73 p < 0.01 – – – [29] 
1995 128 NS – – p < 0.05 [30] 
1999 36 p < 0.05 – – – [31] 
2002 86 NS – – – [32] 
2004 66 p < 0.05 – – – [33] 
2013 3378 p < 0.01 NS NS – [34] 
No. pts; number of patients, GS; Gleason score, LN; lymph node, NS; not significance, Ref; reference. 
For CRPC in particular, though, MET expression has been reported to be upregulated and is thought 
to play a role in angiogenesis, cell invasion, and metastasis to distant tissues [35]. As mentioned 
previously, in vitro studies have shown a significant correlation between increased Met expression and 
androgen-independent growth [23,24]. These in vitro and in vivo findings suggest that the expression of 
Met is correlated with the emergence of castration-resistant tumor growth, and that Met is a potential 
therapeutic target in CRPC.  
2.3. MET-Targeting Therapies for Patients with Prostate Cancer  
2.3.1. Cabozantinib  
Cabozantinib (XL184) is an orally bioavailable TKI with potent activity against MET and VEGFR2. 
Cabozantinib blocked the progression of osteolytic and osteoblastic lesions in a xenograft model of 
CRPC in bone [36]. A phase II, randomized, discontinuation trial has been conducted in patients with 
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advanced PCa, showing that cabozantinib has clinical efficacy in men with CRPC [37]. The trial showed 
that cabozantinib led to a reduction in soft tissue lesions, improved progression-free survival (PFS), 
improved resolution of bone scans, decreased levels of bone turnover markers, less pain, and reduced 
narcotic use. Two phase III clinical trials were done in men with metastatic CRPC. The first is the 
Cabozantinib Met Inhibition CRPC Efficacy Trial (COMET)-1 (NCT01605227), which aims to  
evaluate the efficacy of cabozantinib compared to prednisone. In this study, the overall survival of men 
previously treated for metastatic CRPC with bone-dominant disease, who have experienced disease 
progression on docetaxel-containing chemotherapy, abiraterone or MDV3100, was assessed. The second 
study is the Cabozantinib Met Inhibition CRPC Efficacy Trial (COMET)-2 (NCT01522443). This study 
aims to evaluate the effect of cabozantinib versus mitoxantrone plus prednisone on pain response and 
bone scan response in men with CRPC. However, COMET-1 did not meet demonstrating a statistically 
significant increase in overall survival, and based on the outcome of COMET-1, enrollment in COMET-2 
was halted. 
2.3.2. Tivantinib  
Another small molecule inhibitor of Met, tivantinib (formerly ARQ 197), is being studied in PCa.  
A phase I trial of ARQ 197 was conducted to evaluate the safety of tivantinib. The study showed that 
tivantinib safely inhibited intratumoral c-MET signaling, but no responses, according to the Response 
Evaluation Criteria in Solid Tumors, were observed [38]. A phase II trial is ongoing in men with 
asymptomatic or minimally symptomatic metastatic CRPC (NCT01519414). The purpose of this trial is 
to investigate the efficacy of tivantinib compared to placebo for treating patients with metastatic PCa.  
2.3.3. Sorafenib 
Sorafenib is a multikinase inhibitor targeting Raf kinase (serine-threonine kinase) and tyrosine 
kinases, including VEGFR, platelet-derived growth factor receptor (PDGFR), c-kit, c-Met. A phase II 
trial of sorafenib monotherapy for CRPC reported relative tolerance of this agent. However, although 
initially 2 of 22 patients treated with sorafenib showed evidence of improved bony metastatic lesions, 
most patients (21 of 22) had disease progression [39]. 
2.3.4. Sunitinib 
Sunitinib is an oral multitargeted inhibitor of VEGFR, PDGFR, c-kit, FLT-3, and c-Met. A phase III 
trial that evaluated angiogenesis-targeted sunitinib therapy in a randomized, double-blind trial of 
metastatic CRPC concluded that the addition of sunitinib to prednisone did not improve OS compared 
with placebo in docetaxel-refractory metastatic CRPC [40].  
2.3.5. Cause of Failure in MET-Targeting Therapies 
As mentioned above, various types of MET inhibitors have been studied in clinical trials. However, 
unfortunately, almost of them showed “negative” results. As reason of such failure, several factors 
including study design, patient’s selection, and unexpected side effect are speculated. In this review, we 
emphasize the fact that such molecular-targeting therapies used for patients with CRPC. In addition, in 
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many cases, CRPC patients were previously treated with docetaxel prior to such therapies. From these 
facts, we believe that more detailed information regarding pathological roles of Met expression in 
patients with CRPC are essential to improve the anti-tumor effect.  
3. Renal Cell Carcinoma 
Renal cell carcinoma (RCC) is the third most frequent cancer originating from the genitourinary 
organs. It is estimated that 65,000 patients were diagnosed with RCC in the United States in 2013 [17]. 
RCC originates from the proximal tubule of the kidney or the collecting duct and is classified into four 
major histological types: clear cell (conventional), papillary, chromophobe, and collecting duct. Among 
these, clear cell (conventional) RCC is the most common histological type and accounts for 75%–80% 
of all cases. Papillary RCC is the second most common histological type and accounts for 10%–15% of 
cases. Papillary RCC can be further divided into two morphological subtypes; type 1 consists of 
predominantly basophilic cells and type 2 consists of mostly eosinophilic cells. In recent years, 
cytogenetic and molecular studies have indicated that these different RCC pathological types possess 
different characteristics and respond differently to therapies. For example, papillary RCC is more 
frequent in male patients and tends to be of a low stage compared to clear cell or chromophobe  
RCC [41]. Therefore, it is necessary to discuss the pathological role of Met according to the different 
subtypes. Inactivation of the von Hippel-Lindau (VHL) gene should also be considered in this discussion 
of the pathological characteristics and molecular mechanisms of RCC.  
3.1. The Function of Met Expression in Papillary RCC 
The clinical significance and pathological role of MET has been most widely investigated, and is best 
understood, in papillary RCC. Several activating missense mutations of the MET gene have been 
described in individuals with papillary RCC [42]. Several mutations in the MET TK domain, both in the 
germline of hereditary papillary RCC families (M1131T, V1188L, D1228H, Y1230C) and in a subset 
of sporadic papillary RCC patients (L1195V, D1228H, Y1230H, M1250T), have been described [43]. 
Similar trends in hereditary papillary RCC have also been reported in another study [44]. Research on 
MET and papillary RCC reported the interaction between c-MET and VEGF; the development of 
resistance to VEGF-targeted therapy correlated with the up-regulation of c-MET expression. This result 
suggests that the acquired resistance to VEGF pathway inhibitors is frequently mediated by the activation 
of alternative signaling pathway (angiogenic escape), which induces c-MET overexpression [45]. 
3.2. The Function of Met Expression in Clear Cell RCC and Other RCCs 
The most well-known form of inherited clear cell RCC is that associated with VHL syndrome. 
Inactivation of VHL gene function by mutation or methylation is found in patients with sporadic clear 
cell RCC, although it is rare in other histological RCC types. Several reports have found that Met  
protein is detectable in human clear cell RCC tissues [46–49]. VHL expression in RCC cells suppresses 
MET/β-catenin signaling, and a loss of VHL in conventional RCC has been shown to enable MET/β-catenin 
signaling in vitro [50]. Thus, it has been suggested that Met plays important roles in the carcinogenesis 
and malignant behavior of clear cell RCC via direct and indirect mechanisms.  
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3.3. Expression/Activation of MET in Renal Cell Carcinomas and Correlation with 
Clinicopathological Features 
Strong expression of MET is observed in almost all papillary RCC and collecting duct carcinoma, 
however, it is uncommon in clear cell RCC and chromophobe RCC [48]. Gibney et al. have also reported 
that MET expression in papillary RCC and sarcomatous RCC is significantly higher than in clear cell 
RCC subtypes [51]. Thus, Met overexpression is speculated to be a characteristic of papillary RCC.  
It has been reported that MET expression is positively correlated with the nuclear grade, sarcomatoid 
component, and lymphatic invasion in patients with clear cell RCC [48]. Furthermore, the presence of 
phosphorylated MET is reported to be significantly correlated with malignancy aggressiveness and 
prognosis in clear cell RCC [52]. The clinical significance and prognostic role of MET in other types of 
RCC, including chromophobe and collecting duct carcinoma, is not fully understood. A summary of the 
correlations between MET expression and the clinicopathological features including malignant potential 
and survival of patients with RCC is shown in Table 3.  
Table 3. Relationship between MET expression and grade, tumor stage, and prognosis for 
patients with renal cell carcinoma. 
Year No. pts 
Pathological Features 
Survival Ref. 
High Grade pT Stage Lymph Node Metastasis Distant Metastasis 
2006 114 NS NS NS NS NS [52] 
2006 96 p < 0.01 NS NS NS - [48] 
2007 66 - P < 0.01 - p < 0.05 p < 0.01 [47] 
2013 317 p < 0.01 - - - p < 0.05 [51] 
No. pts; number of patients, NS; not significant, Ref.; reference. 
3.4. Met-Targeted Therapies for Patients with Renal Cell Carcinoma 
3.4.1. Foretinib (XL880) 
The drug foretinib, formerly XL880, is a multi-targeted receptor TKI that targets the MET, VEGFR2, 
platelet derived growth factor receptor (PDGFR) β, Tie-2, recepteur d'origine nantais (RON), KIT, and 
FLT3 receptors. A phase I study of foretinib has been completed, and two out of four patients with 
papillary RCC showed a partial response (PR) [53]. A phase II study of foretinib in patients with 
papillary RCC was open-label and nonrandomized [54]. In this study, 74 patients were enrolled and an 
overall response rate of 13.5% with a median PFS of 9.3 months was demonstrated. The most frequent 
adverse events in patients with any grade RCC were fatigue, hypertension, gastrointestinal toxicities, 
and pulmonary emboli. Interestingly, among patients with germline MET mutations, five (50%) of  
ten experienced a PR, and the remaining five (50%) patients had stable disease as the best response.  
A PR was seen in only five (9%) of 57 patients without germline MET mutations. Further investigations 
are necessary to clarify these results.   
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3.4.2. Tivantinib (ARQ197) 
Tivantinib (ARQ197) is an inhibitor of Met receptor TK activity. In vitro studies indicate that 
tivantinib inhibits colony formation in ACHN and 769P cells [51]. Following completion of a phase I 
dose-finding study [55], phase II trials are ongoing in patients with metastatic papillary RCC 
(NCT00345423). 
3.4.3. Cabozantinib (XL184) 
Recently, a phase I study of cabozantinib (XL184), a small molecule inhibitor of TKs including MET 
and VEGFR2, was performed [56]. The study enrolled 25 patients with metastatic clear cell RCC for 
whom standard therapy had failed. Common adverse events included fatigue, diarrhea, nausea, 
proteinuria, decreased appetite, palmar-plantar erythrodysesthesia, and vomiting. PR was reported in  
seven patients (28%) with a median PFS of 12.9 months and a median overall survival of 15.0 months. 
From these preliminary data, a phase II study randomizing patients to cabozantinib or sunitinib in the 
first-line setting for mRCC has been initiated [45]. In papillary RCC, a special role for c-MET inhibitors 
may emerge because of the critical role of activating c-MET mutations [46]. 
4. Urothelial Cancer 
Urothelial carcinoma (UC), especially bladder cancer, is the second most common genitourinary 
malignancy; it accounts for almost 5% of all newly diagnosed cancers. It is estimated that 72,570 patients 
were newly diagnosed with UC of the bladder in the United States in 2013. More than 90% of cases 
pathologically originate from urothelial cells. Papillary UCs are typically superficial at first presentation 
and are often multifocal. These tumors recur with a high frequency (>60%), and 10%–15% of them will 
progress to life-threatening malignancies over a longer period of time [17,57]. Several risk factors can 
be used to predict tumor progression, including histological grading, stage classification, tumor 
morphology, and the size and number of tumors [58–63]. The number of tumors and their classification 
stage are considered the most important prognostic factors for recurrence [59–64]. Patients with invasive 
and/or metastatic lesions have a poor prognosis. Tumor invasion and metastasis are regulated by 
complex mechanisms, including tumor growth, degeneration of stromal tissues, cell migration, and 
angiogenesis. Moreover, bladder cancer is characterized by distinct molecular characteristics. For 
example, FGR3 mutations are associated with low-stage and low-grade tumors, whereas p53 mutations 
are associated with high-stage and high-grade tumors [65,66]. Therefore, detailed information regarding 
these mechanisms is essential to formulate appropriate treatment and observation strategies for patients 
with UC [67]. In addition to MET expression, interaction with the Axl and PDGFR-α pathways 
contributes to bladder cancer progression [68]. RON, a macrophage-stimulating protein, is a distinct 
receptor TK in the Met proto-oncogene family [69]. Co-expression of RON and MET is significantly 
associated with decreased overall and metastasis-free survival [70]. RON-associated signaling may also 
play an important role in the progression of human bladder cancer. Some researchers have suggested 
that cross-talk exists between the RON and Met pathways [71,72]. Evaluation of RON and Met expression 
status may help to identify a subset of bladder cancer patients who require more intensive treatment. 
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4.1. Function of Met Expression in UC 
In UC cell lines, Met mRNA has been detected by northern blot analysis [73] and reverse transcriptase 
polymerase chain reaction [74]. In the absence of point mutations, the expression of Met tends to 
positively correlate with cancer cell line differentiation [59]. However, since most of these studies have 
been in vitro, a detailed understanding of the pathological significance and regulative mechanism of 
MET in UC cells has not been achieved. 
4.2. Expression/Activation of Met in UC and Correlation with Clinicopathological Characteristics 
It was initially reported that Met expression could not be detected in the normal urothelium or in cases 
of UC of the kidney [75]. However, more recently, Met expression in urothelial cells, endothelial cells, 
and smooth muscle cells of the urinary organs has been detected [76]. A previous study had reported 
that the expression of Met in UC cells of the urinary bladder was positively associated with histological 
grading, non-papillary contour, tumor size, and muscle invasion [77]. In another study, antibody arrays 
were used to demonstrate that MET was strongly expressed in high-grade cases of bladder cancer [78]. 
However, some researchers have found contradictory results (Table 4). Thus, there is no general 
agreement on the relationship between MET expression and pathological features in patients with UC. 
However, in recent years, the consensus is that Met may play an important role in the carcinogenesis 
and malignancy aggressiveness in patients with UC [76,79,80]. Strong MET expression has been 
demonstrated in an invasive phenotype of bladder cancer [76], although varying levels of MET 
immunostaining are consistently detected in UC of the bladder [59]. In regard to correlation between 
MET expression and outcome in patients with bladder cancer, several reports have indicated that MET 
levels do correlate with the progression and several studies have shown that its overexpression is 
associated with shortened metastasis-free and overall survival in patients with bladder cancer [68,77,78]. 
These pathological significances and predictive roles of MET expression were showed in Table 4. 
Table 4. Relationship between MET expression and pathological features and survival in 
urothelial carcinoma. 
Year No. pts 
Clinicopathological Features Outcome 
Ref. 
Grade T Stage N Stage M Stage PD Survival 
1998 49 NS NS NS -  NS [79] 
2002 142 p < 0.01 p < 0.01 p < 0.01 - p < 0.01 p < 0.05 [59] 
2005 183 p < 0.01 p < 0.01 – - NS p < 0.05 [69] 
2006 173 p < 0.01 p < 0.01 p < 0.01 -  p < 0.05 [78] 
2009 133 p < 0.01 p < 0.01 p = 0.01  NS NS [52] 
2011 75 NS NS NS NS  p < 0.01 [68] 
No. pts; number of patients, PD, progression of disease, Ref; reference, NS; not significant. 
The biological activities of Met are exerted by phosphorylation, and phosphorylation of Met is 
essential for the stimulation of downstream signaling pathways. For this reason, Miyata et al. [52] 
investigated the clinical significance and pathological function of MET phosphorylation in human 
bladder cancer tissues and found that MET expression was not a significant predictor of metastasis-free 
or cause-specific survival. However, phosphorylated MET was significantly associated with tumor 
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aggressiveness and prognosis in patients with bladder cancer patients. In addition, among the different 
MET phosphorylation sites, phosphorylation of Y1349 was thought to play an important role in 
metastasis and survival. Phospho-Y1349 MET was correlated with the expression of matrix 
metalloproteinase-2 and -7, and E-cadherin [52]. 
4.3. Met-Targeted Therapy for Patients with Urothelial Carcinoma 
Based on the pathological significance and prognostic role of MET in UC cells, many investigators 
have suggested that Met is a potential novel therapeutic target for these patients. SU-11274, a selective 
MET kinase inhibitor, is reported to affect the growth of bladder cancer [81]. In addition, several reports 
have shown that tumor growth and invasion by UC is inhibited by regulation of the HGF-Met signaling 
system [82,83]. However, to our knowledge, no clinical trial using a Met inhibitor is ongoing at present. 
Furthermore, a combination of TKIs could induce a synergistic antitumor effect, and improve therapeutic 
efficacy [84]. In the future, detection of Met co-expression molecules, combined with more selective, or 
multi-targeting, TKIs could enable individualized therapy in UC. 
5. Conclusions 
In this review, we have summarized the pathological role, clinical significance, and predictive value 
of Met in urological cancer in vivo and in vitro. In addition, we have reviewed the preclinical studies 
and clinical trials of Met-targeted therapies in patients with urological cancers. Numerous investigators 
have focused on the functions of Met at a genetic, molecular, and clinical level. However, much is still 
unknown. Based on previous reports and current studies, we believe that Met has the potential to be used 
as a predictive factor and therapeutic target in patients with urological cancers.  
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